Pathogenicity of microbes associated with cystic fibrosis

Microbes and Infection

Volumn 1, Issue 12, 1999, Pages 1005-1014

  Hutchison, Michael L ^a   Govan, John R W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bacteria; Cystic fibrosis; Infection; Virulence

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; MUCIN; NITRIC OXIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALCALIGENES; ASPERGILLUS; BACTERIAL VIRULENCE; BORDETELLA; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; HAEMOPHILUS INFLUENZAE; INFECTION SENSITIVITY; LIFE EXPECTANCY; LUNG INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RALSTONIA; REVIEW; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

ALCALIGENES; ASPERGILLUS; BACTERIA (MICROORGANISMS); BORDETELLA; BURKHOLDERIA; BURKHOLDERIA CEPACIA; HAEMOPHILUS INFLUENZAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RALSTONIA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0032696604     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80518-8     Document Type: Review

References (71)

1. Govan J.R.W., Nelson J.W. Microbiology of lung infection in cystic fibrosis. Br. Med. Bull. 48:1992;912-930.
2. Trivier D., Houdret N., Courcol R.J., Lamblin G., Roussel P., Davril M. The binding of surface proteins from Staphylococcus aureus to human bronchial mucins. Eur. Resp. J. 10:1997;804-810.
3. Imundo L., Barasch J., Prince A., Alawqati Q. Cystic-fibrosis epithelial-cells have a receptor for pathogenic bacteria on their apical surface. Proc. Natl. Acad. Sci. USA. 92:1995;3019-3023.
4. Aly R., Levit S. Adherence of Staphylococcus aureus to squamous epithelium: role of fibronectin and teichoic acid. Rev. Infect. Dis. 9:1987;S341-S349.
5. Saiman L., Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J. Clin. Invest. 92:1993;1875-1880.
6. Cohen M.L. Staphylococcus aureus: Biology, mechanisms of virulence, epidemiology. J. Pediatr. 108:1986;796-799.
7. Kreiswirth B., Kornblum J., Arbeit R.D., Eisner W., Maslow J.N., McGreer A., Low D.E., Novick R.P. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science. 259:1993;227-230.
8. Musser J.M., Kapur V. Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources - Association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J. Clin. Microbiol. 30:1992;2058-2063.
9. Coia J.E., Browning L., Haines L., Birbeck T.H., Platt D.J. Comparison of enterotoxins and haemolysins produced by methicillin-resistant (MRSA) and sensitive (MSSA) Staphylococcus aureus. J. Med. Microbiol. 36:1992;164-171.
10. Chan P.F., Foster S.J. The role of environmental factors in the regulation of virulence-determinant expression in Staphylococcus aureus 8325-4. Microbiology. 144:1998;2469-2479.
11. Sponer M., Nick H.P., Schnebli H.P. Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol. Chem. Hoppe-Seyler. 372:1991;963-970.
12. Kahl B., Herrmann M., Everding A.S., Koch H.G., Becker K., Harms E., Proctor R.A., Peters G. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 177:1998;1023-1029.
13. Balwit J.M., Vanlangevelde P., Vann J.M., Proctor R.A. Gentamycin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J. Infect. Dis. 170:1999;1033-1037.
14. Massion P.P., Herbert C.A., Leong S., Chan B., Inoue H., Grattan K., Sheppard D., Nadel J.A. Staphylococcus aureus stimulates neutrophil recruitment by stimulating Interleukin-8 production in dog trachea. Am. J. Physiol. Lung Cell. Molec. Physiol. 12:1995;L85-L94.
15. Campos J., Román F., Georgiou M., García C., Gómez-Lus R., Cantón R., Escobar H., Baquero F. Long-term persistence of cpirofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J. Infect. Dis. 174:1996;1345-1347.
16. Barsum W., Wilson R., Read R.C., Rutman A., Todd H.C., Houdret N., Roussel P.R., Cole P.J. Interaction of fimbraited and nonfimbriated strains of unencapsulated Haemophilus influenzae with human respiratory tract mucus in vitro. Eur. Resp. J. 8:1995;709-714.
17. Johnson A.P., Inzana T.J. Loss of ciliary activity in organ cultures of rat trachea treated with lipopolysaccharide isolated from Haemophilus influenzae. J. Med. Microbiol. 22:1986;265-268.
18. Tsang K.W.T., Rutman A., Kanthakumar K., Palmer A., Roberts D., Tillotson G., Cole P.J., Wilson R. The effects of low concentrations of antibiotics on epithelial damage caused by non-typable Haemophilus influenzae and bacterial morphology. J. Antimicrob. Chemother. 36:1995;545-549.
19. Govan J.R.W., Deretic V. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:1996;539.
20. Barth A.L., Pitt T. Auxotrophic variants of Pseudomonas aeruginosa are selected from prototrophic wild-type strains in respiratory infections in patients with cystic fibrosis. J. Clin. Microbiol. 33:1995;37-40.
21. Pier G.B. Pseudomonas aeruginosa: a key problem in cystic fibrosis. ASM News. 6:1998;339-347.
22. VanDelfson C., Iglewski B.H. Cell-to-cell signalling and Pseudomonas aeruginosa infections. Emerg. Infect. Dis. 4:1998;551-560.
23. Doggett R.G. Incidence of Pseudomonas aeruginosa from clinical sources. Appl. Microbiol. 18:1969;936-937.
24. Doggett R.G., Harrison G.M., Wallis E.S. Comparison of some properties of Pseudomonas aeruginosa isolated from infections in persons with and without cystic fibrosis. J. Bacteriol. 87:1964;427-431.
25. Valerius N.H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 338:1991;725-726.
26. Tredgett M.W., Doherty C., Govan J.R.W. Incidence of common pyocin types of Pseudomonas aeruginosa from patients with cystic fibrosis, and chronic airways disease. J. Med. Microbiol. 32:1990;169-172.
27. Nelson J.W., Tredgett M.W., Sheehan J.K., Thornton D.J., Notman D., Govan J.R.W. Mucinophilic and chemotactic properties of Pseudomonas aeruginosa in relation to pulmonary colonization in cystic fibrosis. Infect. Immun. 58:1990;1489-1495.
28. Feldman M., Bryan R., Rajan S., Scheffler L., Brunnert S., Tang H., Prince A. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 66:1998;43-51.
29. Davies J., Stern M., Dewar A. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelial cells. Am. J. Resp. Cell Mol. Biol. 16:1997;657-666.
30. DeBentzmann S., Roger P., Dupuit F., Bajoletlaudinat O., Plotowski M.C., Puchelle E. Asialo GM1 is a receptor for Psuedomonas aeruginosa adherence to regenerating respiratory epithelia cells. Infect. Immun. 64:1996;1582-1588.
31. Pier G.B., Grout M., Zaidi T.S., Olsen J.C., Johnson L.G., Goldberg J.B. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. 271:1996;64-67.
32. Goldman M.J., Anderson G.M., Stolzenberg E.D., Kari U.P., Zasloff M., Wilson J.M. Human beta-defensin is a salt-sensitive antibiotic in lung that is activated in cystic fibrosis. Cell. 88:1997;553-560.
33. Smith J.J., Travis S.M., Greenberg E.P., Welsh M.J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 85:1996;229-236.
34. Morrison G.M., Davidson D.D., Kilanowski F.M., Borthwick D.W., Crook K., Maxwell A.I., Govan J.R.W., Dorin J.R. Mouse beta defensin-1 is a functional homolog of human beta defensin-1. Mam. Genome. 10:1998;453-457.
35. Gosselin D., Stevenson M.M., Cowley E.A. Impaired ability of CFTR knockout mice to control lung infection with Pseudomonas aeruginosa. Am. J. Resp. Crit. Care M. 157:1998;1253-1262.
36. Dohrman A.F., Miyata S., Gallup M., Li J.D., Chaplin C., Coste A., Escudier E., Nadel J.A., Basbaum C. Mucin gene (MUC2 and MUC5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim. Biophys. Acta. 1406:1998;251-259.
37. Baeuerle P.A., Henkel T. Function and activation of NF-kappa-B in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
38. Balfourlynn I.M., Laverty A., Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch. Dis. Childhood. 75:1996;319-322.
39. Meng Q.H., Springall D.R., Bishop A.E. Lack of inducible nitric oxide synthase in bronchial epithelium: A possible mechanism of susceptibility to infection in cystic fibrosis. J. Pathol. 184:1998;323-331.
40. Isles A., Maclusky I., Corey M., Gold R., Prober C., Flemming P., Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:1984;206-210.
41. Gilligan P.H. Microbiology of airway disease in patients with cystic fibrosis. J. Clin. Microbiol. Rev. 4:1991;35-51.
42. Gladman G., Connor P.J., Williams R.F., David T.J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch. Dis. Childhood. 67:1992;192-195.
43. Tablan O.C., Carson L.A., Cusick L.B., Bland L.A., Martone W.J., Jarvis W.R. Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from stimulated sputum specimens of patients with cystic fibrosis. J. Clin. Microbiol. 25:1987;485-487.
44. Govan J.R.W., Hughes J.E., Vandamme P. Burkholderia cepacia: medical taxonomic and ecological issues. J. Med. Microbiol. 45:1996;395-407.
45. Rodley P.D., Romling U., Tummler B. A physical genome map of the Burkholderia (Pseudomonas) cepacia type strain. Mol. Microbiol. 17:1995;57-67.
46. Lessie T.G., Hendrickson W., Manning B.D., Devereux R. Genomic complexity and plasticity of Burkholderia cepacia. FEMS Microbiol. Lett. 144:1996;117-128.
47. Mack K., Titball R.W. The detection of insertion sequences within the human pathogen Burkholderia pseudomallei which have been identified previously in Burkholderia cepacia. FEMS Microbiol. Lett. 162:1998;69-74.
48. Vandamme P., Holmes A., Vanccanneyt M., Coenye T., Coopman R., Revets H., Lauwers S., Gillis M., Kersters K., Govan J.R.W. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans speceies. Int. J. Syst. Bact. 47:1997;1200.
49. Trépanier S., Prince A., Huletsky A. Characterisation of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob. Agents Chemother. 41:1997;2399-2405.
50. Burns J.L., Wadsworth C.D., Barry J.J., Goodall C.P. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding and outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob. Agents Chemother. 40:1996;307-313.
51. Scordilis G.E., Ree H., Lessie T.G. Identification of transposable elements which activate gene expression in Pseudomonas cepacia. J. Bacteriol. 169:1987;8-13.
52. Hutchison M.L., Poxton I.R., Govan J.R.W. Burkholderia cepacia produces a hemolysin that is capable of inducing degranulation and apoptosis of mamaliam phagocytes. Infect. Immun. 66:1998;2033-2039.
53. Abe M., Nakazawa T. Characterisation of hemolytic and antifungal substance, cepalycin from Pseudomonas cepacia. Microbiol. Immunol. 38:1994;1-9.
54. Abe M., Nakazawa A. The dsbB gene product is required for protease production by Burkholderia cepacia. Infect. Immun. 64:10-1996;4378-4380.
55. Lonon M.K., Woods D.E., Straus D.C. Production of lipase by clinical isolates of Pseudomonas cepacia. J. Clin. Microbiol. 26:1988;979-984.
56. Speert D.P., Bond M., Woodman R.C., Curnutte J.T. Infection with Pseudomonas cepacia in chronic granulomatous disease - Role of non-oxidative killing by neutrophils in host defense. J. Infect. Dis. 170:1994;1524-1531.
57. Shaw D., Poxton I.R., Govan J.R.W. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol. Med. Microbiol. 11:1995;99-106.
58. Hughes J.E., Stewart J., Barclay G.R., Govan J.R.W. Priming of Neutrophil Respiratory Burst Activity by Lipopolysaccharides from Burkholderia cepacia. Infect. Immun. 65:1997;4281-4287.
59. Vasil M.L., Krieg D.P., Kuhns J.S., Ogle J.W., Shortridge V.D., Ostroff R.M., Vasil A.I. Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia. Infect. Immun. 58:1990;4020-4029.
60. Nakazawa T., Yamada Y., Ishibashi M. Characterization of hemolysin in extracellular products of Pseudomonas cepacia. J. Clin. Microbiol. 25:1987;195-198.
61. Lim Y., Suh J.W., Kim S., Hyun B., Kim C., Lee C.H. Cepacidine A, a novel antifungal antibiotic produced by Pseudomonas cepacia. J. Antibiot. 47:1994;1407-1416.
62. McKevitt A.I., Bajaksouzian S., Klinger J.D., Woods D.E. Purification and characterization of an extracellular protease from Pseudomonas cepacia, Infect. Immun. 57:1989;771-778.
63. Sajjan U.S., Sun L., Goldstein R., Forstner J.F. Cable (cbl) type-II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia - Nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers. J. Bacteriol. 177:1995;1030-1038.
64. Sun L., Jiang R.Z., Steinbach S., Holmes A., Campanelli C., Forstner J., Sajjan U., Tan Y., Riley M., Goldstein R. The emergence of a highly transmissable lineage of CBL+ Pseudomonas (Burkholderia) cepacia causing CF center epidemics in north-America and Britain. Nature M. 1:1995;661-666.
65. Barth A.L., Pitt T.L. Auxotrophy of Burkholderia (Pseudomonas) cepacia from cystic fibrosis patients. J. Clin. Microbiol. 33:1995;2192-2194.
66. Nelson J.W., Butler S.L., Brown P.H., Greening A., Govan J.R.W. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J. Med. Microbiol. 39:1993;39-47.
67. Hutchison M.L., Poxton I.R., Govan J.R.W. Modulation of the host immune response by exported virulence determinants of Burkholderia cepacia. Ped. Pulmonol. Suppl. 17:1998;377-377.
68. Frederiksen B., Høiby N., Koch C. Stenotrophomonas (Xanthomonas) maltophilia at the Danish cystic fibrosis centre 1974-1993, Abstr 383. Pediatr. Pulmonol. 12:1995;287.
69. Denton M., Todd N.J., Littlewood J.M. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;402-405.
70. Demko C.A., Stern R.C., Doershuk C.F. Stenotrophomonas maltophilia in cystic fibrosis. Ped. Pulmonol. 25:1998;304-308.
71. Denton M. Stenotrophomonas maltophilia: An emerging problem in cystic fibrosis patients. Rev. Med. Microbiol. 8:1997;15-19.